<DOC>
	<DOCNO>NCT00116350</DOCNO>
	<brief_summary>The purpose study test whether misoprostol effective oxytocin treat primary postpartum hemorrhage ( PPH ) uterine atony suspect cause two circumstance : 1 ) woman receive prophylactic uterotonics third stage labor ; 2 ) prophylactic uterotonics give third stage labor .</brief_summary>
	<brief_title>Misoprostol Treatment Postpartum Hemorrhage</brief_title>
	<detailed_description>Postpartum hemorrhage ( PPH ) remain major cause maternal death worldwide . Misoprostol offer several advantage oxytocin ergometrine , drug currently use treat PPH . For example , misoprostol stable high temperature shelf life several year , easy administer , give hypertensive patient , inexpensive . This randomized , double-blind placebo-controlled trial test whether misoprostol effective oxytocin treat primary PPH hospital birth , woman receive prophylactic uterotonics third stage labor . Blood loss measure consent woman deliver vaginally . If PPH occur uterine atony suspect cause , woman randomize receive either : ) four 200 µg pill misoprostol sublingually IV saline ( resemble oxytocin ) b ) four placebo tablet resemble misoprostol sublingually 40 IU oxytocin IV . This study seek answer follow question : - Is misoprostol effective oxytocin treatment primary PPH woman receive oxytocin prophylaxis third stage labor ? - Does misoprostol acceptable safety profile give 800 µg sublingual dose treat PPH ? - Is side effect profile misoprostol acceptable woman ? This study take place hospital locate Burkina Faso , Ecuador , Egypt , Turkey , Vietnam .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>Vaginal delivery Postpartum hemorrhage due suspect uterine atony Depending study group : administration prophylactic uterotonics third stage labor Known allergy misoprostol prostaglandin Csection current delivery</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Postpartum hemorrhage</keyword>
	<keyword>Misoprostol</keyword>
	<keyword>Developing country</keyword>
	<keyword>Maternal morbidity</keyword>
	<keyword>Randomized control trial</keyword>
</DOC>